至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Reclassification of a likely pathogenic Dutch founder variant in KCNH2; implications of reduced penetrance

Hum Mol Genet. 2022-10; 
Jaël S Copier , Marianne Bootsma , Chai A Ng , Arthur A M Wilde , Robin A Bertels , Hennie Bikker , Imke Christiaans , Saskia N van der Crabben , Janna A Hol , Tamara T Koopmann , Jeroen Knijnenburg , Aafke A J Lommerse , Jasper J van der Smagt , Connie R Bezzina , Jamie I Vandenberg , Arie O Verkerk , Daniela Q C M Barge-Schaapveld , Elisabeth M Lodder
Products/Services Used Details Operation
Plasmid DNA Preparation In brief, DNA plasmids co-express variant and WT KCNH2 allele were ordered from GenScript Inc (Pistcataway, NJ, USA). Get A Quote

摘要

Background: Variants in KCNH2, encoding the hERG channel which is responsible for the rapid component of the cardiac delayed rectifier K+ current (IKr), are causal to Long QT Syndrome type 2 (LQTS2). We identified eight index patients with a new variant of unknown significance (VUS), KCNH2:c.2717C > T:p.(Ser906Leu). We aimed to elucidate the biophysiological effect of this variant, to enable reclassification and consequent clinical decision-making. Methods: A genotype-phenotype overview of the patients and relatives was created. The biophysiological effects were assessed independently by manual and automated calibrated patch-clamp. HEK293a cells expressing: (I) wild type (WT) KCNH2, (II) KCNH2-p.S906L alone ... More

关键词